^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SYHA1815

    i
    Other names: SYHA1815, SYHA-1815, SYHA 1815
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    FGFR inhibitor, RET inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=97, Recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd
    Clinical • New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • FGFR (Fibroblast Growth Factor Receptor) • KDR (Kinase insert domain receptor) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    SYHA1815